Roche Advances Fenebrutinib With 16% CDP Reduction, Building A Broader MS Case Ahead Of FDA Review

Roche is sharpening the commercial and clinical case for fenebrutinib as its FDA filing in multiple sclerosis moves forward, releasing more phase 3 detail on lesion biology, disability progression and brain volume loss. The company has already filed for approval in relapsing and primary progressive MS, and with the FDA having accepted the filing, Roche said it is on track to launch the product next year.

The strategic issue is not simply whether fenebrutinib works on relapses. Roche is trying to position the BTK inhibitor around disability control, an area physicians increasingly see as the decisive battleground for new MS therapies and one that could affect where BTK drugs sit relative to anti-CD20 treatments.

The Data

At the MSToronto2026 conference, Roche linked fenebrutinib to an up to 30% reduction in the volume of slowly expanding lesions and reported a 62% reduction in the accumulation of paramagnetic rim lesions in relapsing MS. The company described the latter as the first prospective demonstration of a therapeutic effect on chronic active lesions in a phase 3 trial, arguing that the findings show fenebrutinib directly targets chronic inflammation in the brain.

Roche also reported a numerical reduction in the risk of 12-week composite confirmed disability progression in its two phase 3 relapsing MS trials. Pooling the relapsing MS data, the company presented a 16% reduction in 12-week composite confirmed disability progression.

In the same oral presentation, Roche said fenebrutinib reduced annual total brain volume loss by 23%. The company’s interpretation is that the combined package points to an ability to control relapses, slow brain tissue loss and preserve function.

The Commercial Picture

Those details matter because disability progression may influence prescribing more than marginal differences on relapse measures. Guggenheim Securities analysts wrote last month that confirmed disability progression is “a potential swing factor” for the MS market, and three experts they spoke with said evidence on that endpoint could justify moving a BTK inhibitor ahead of an anti-CD20 drug in the treatment pathway.

Roche’s commercial expectations are also higher than consensus. Roche Pharmaceuticals CEO Teresa Graham said last month that analyst consensus for peak sales is about 1 billion Swiss francs, or $1.2 billion, but predicted fenebrutinib could “get that in PPMS alone.” That makes the current data release part of a market-shaping argument, not just a scientific update: Roche is trying to establish that fenebrutinib’s value proposition extends into the disability measures that may support broader use.